# Poly Medicure share price today (Poly Medicure Ltd, NSE: POLYMED)

> Poly Medicure share price today: ₹1,496.20 at the NSE close on 3 November 2026, down 25.2% in a year. Poly Medicure (NSE: POLYMED) is worth ₹15,160 crore, trades at a P/E of 47.4 and has closed between ₹1,230.10 and ₹1,943.00 over the past 52 weeks. > Poly Medicure Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. POLYMED · Medical Equipment · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/poly-medicure-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: ₹1,496.20 (−25.2% in a year)
- P/E: 47.4× (lower than 51% of the last 11 years)
- Revenue (Jun 2026): ₹525 Cr (+30.3% on a year ago)
- Profit (Jun 2026): ₹85.0 Cr (−8.6% on a year ago)
- Operating margin: 24.0% (−2.0 points on a year ago)
- ROCE: 12%, FY26
- ROIC: 9.2%, against a 12.0% cost of capital: −2.8 points

The main question: domestic institutions moved +3.6 percentage points over 8 quarters while the business went the other way. ## What is the Poly Medicure share price today? Poly Medicure Ltd's share price was ₹1,496.20 at the close on 3 November 2026. It has been falling for 1 week. That is 9.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,230 and ₹1,943, and at that close it sat 37% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running. Over the last 11 years the share price moved +917% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Poly Medicure this quarter? Two changes stood out: foreign funds (FIIs) cut their stake for 7 quarters in a row and revenue up on a year earlier for 11 quarters in a row (every quarter we can compare). 1. Foreign funds (FIIs) cut their stake for 7 quarters in a row From 12.3% to 5.4% of the company by the September 2026 quarter. 2. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹525 crore, +30.3% on a year earlier. Why: Revenue rose because Europe recovered as new customers came back. From the earnings call on 10 Aug 2026. ## What are Poly Medicure's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Poly Medicure reported revenue of ₹525 crore, up 30.3% from ₹403 crore a year earlier, and a profit of ₹85.0 crore, down 8.6% from ₹93.0 crore. ### Poly Medicure results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹525 crore | ₹403 crore | +30.3% |
| Profit | ₹85.0 crore | ₹93.0 crore | −8.6% |
| Earnings per share | ₹8.49 | ₹9.19 | −7.6% |
| Operating margin | 24.0% | 26.0% | −2.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Poly Medicure's management discussed these results on a call held on 10 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Poly Medicure share price history? Poly Medicure closed at ₹1,496.20 on 3 November 2026, down 25.2% from ₹1,999.70 a year earlier (31 October 2025) and up 64.0% over five years. Its highest weekly close since March 2016 was ₹3,128.90 on 1 November 2024. ### Poly Medicure share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,444.00 | +3.6% |
| 1 month ago · 1 Oct 2026 | ₹1,638.10 | −8.7% |
| 6 months ago · 30 Apr 2026 | ₹1,512.10 | −1.1% |
| 1 year ago · 31 Oct 2025 | ₹1,999.70 | −25.2% |
| 3 years ago · 3 Nov 2023 | ₹1,462.45 | +2.3% |
| 5 years ago · 4 Nov 2021 | ₹912.15 | +64.0% |
| 10 years ago · 4 Nov 2016 | ₹192.60 | +676.8% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹147.15 | +916.8% |
| Highest weekly close since March 2016 · 1 Nov 2024 | ₹3,128.90 | −52.2% |
| Lowest weekly close since March 2016 · 6 May 2016 | ₹135.50 | +1,004.2% |
| 52-week high (weekly close) · 14 Nov 2025 | ₹1,943.00 | −23.0% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹1,230.10 | +21.6% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Poly Medicure? 3 Nov 2026: Poly Medicure closed at ₹1,496.20, up 3.6% on the week and down 8.7% on the month. 28 Aug 2026: ex-date for a dividend of ₹3.50 a share, record date 29 Aug 2026. ### Earlier

- 10 Aug 2026: Poly Medicure held its results call for April to June 2026. Management guided: FY27 consolidated revenue ₹2,300-2,400 crore, including full-year Pendra Care and Citieffe consolidation. - Results for April to June 2026: Revenue up 30.3% and profit down 8.6% on a year earlier. ## What dividend does Poly Medicure pay? Poly Medicure paid ₹3.50 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.23% at the ₹1,496.20 close on 3 November 2026. The last was a dividend of ₹3.50 a share, ex-date 28 August 2026. ### Poly Medicure dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 28 Aug 2026 | ₹3.50 | Dividend | 29 Aug 2026 |
| 18 Sep 2025 | ₹3.50 | Dividend | same day |
| 19 Sep 2024 | ₹3 | Dividend | n/a |
| 21 Sep 2023 | ₹3 | Dividend | n/a |
| 16 Sep 2022 | ₹2.50 | Dividend | n/a |
| 16 Sep 2021 | ₹2.50 | Dividend | 17 Sep 2021 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Poly Medicure Ltd paid out 11% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Poly Medicure management say on the latest results call? On the call for April to June 2026, held on 10 August 2026, Poly Medicure's management guided: FY27 consolidated revenue ₹2,300-2,400 crore, including full-year Pendra Care and Citieffe consolidation. > “We have enough on our plate right now with the existing businesses, and I do not think we will be ready to launch anything substantially new in the next few years.”
> Himanshu Baid, on the call for April to June 2026

### What management guided

- FY27 standalone revenue ₹1,900-2,000 crore; domestic growth above 20% and international growth above 15%. - FY27 operating margin: standalone 25-27%, expected toward the upper end, and consolidated 23-25%. - Steady-state gross margin 68-69% standalone and 71-72% consolidated. - FY27 capital spending ₹200-225 crore; Faridabad-Palwal planned by March 2027 and Noida commercially in April to June 2027. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/3982/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 10 August 2026.)

## What to watch in Poly Medicure's next results? When Poly Medicure reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Q2 revenue acceleration after the initial price-hike disruption - check standalone and organic consolidated growth against the maintained annual framework. - What to check (from the call)
- Q2 revenue acceleration after the initial price-hike disruption - check standalone and organic consolidated growth against the maintained annual framework. - Middle East port backlog and container availability - check whether intact customer demand converts into resumed shipments. - Renal recovery and anti-dumping progress - check pricing, distribution traction and regulatory movement. - Pendra Care and Citieffe integration - check regulatory approvals, cross-sales visibility and production-transfer progress. ## Which stock lists is Poly Medicure on? Poly Medicure is on one of our India lists: Small & mid cap stocks. [Small & mid cap stocks Size rank in India: 437](https://www.sectoralpha.in/small-cap-stocks-india)

## Is Poly Medicure profitable? Poly Medicure Ltd earned ₹85.0 Cr of net profit in the Jun 2026 quarter, −8.6% on the same quarter a year earlier. Full-year FY26 profit was ₹321 Cr. Over 10 years profit has grown 20.9% a year on average. That is 16.2% of the quarter's revenue. The same quarter a year earlier earned ₹93.0 Cr. For the full year, FY26 profit was ₹321 Cr (−5.3% on the year before). Why profit moved: revenue changed +30.3% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −12.2% and revenue +18.4%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Poly Medicure make, and is it growing? Poly Medicure Ltd reported ₹525 Cr of revenue in the Jun 2026 quarter, +30.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 16.4% a year on average. The last full year, FY26, came in at ₹1,875 Cr. The last four reported quarters add to ₹1,998 Cr. FY26 revenue was ₹1,875 Cr, +12.3% on the year before. Recent pace: the last four quarters grew +18.4% on average, against 16.4% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +18.4%, against +17.8% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −12.3%, against +7.9% a year (rolling over). ## How much of every ₹100 of sales does Poly Medicure keep? Poly Medicure Ltd's operating margin was 24.0% in the Jun 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 21.0% and 28.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −2.4 percentage points on the year while gross margin changed +5.0 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Poly Medicure's profit turning into cash? Over the last 3 years, 81% of Poly Medicure Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹246 Cr of operating cash against ₹321 Cr of profit. After ₹724 Cr of spending on assets, free cash was −₹478 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 81% of profit came in as cash: the cash cycle got 156 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 5.1× depreciation over three years. The next section checks what that spending is building. ## Where does Poly Medicure's cash go? Poly Medicure Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 335 days in FY26, up from 179 days in FY21. It spent ₹1,342 Cr on assets over the last 3 years. Customers take 103 days to pay, and stock sits for 323 days on average. At FY26 sales of ₹1,875 Cr, each day of that cycle ties up about ₹5.1 Cr, so roughly ₹1,721 Cr is tied up in the business at any time. FY26: customers took 103 days to pay and stock sat for 323 days, about 10.6 months of sales sitting as stock, for a full cycle of 335 days, longer than FY21's 179. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 323 days. Customers pay about 103 days after that. Suppliers are paid at 91 days. Together that makes the 335-day cycle. Spending on assets: ₹1,342 Cr over the last 3 years, against ₹262 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹99.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Poly Medicure's P/E ratio, and how does it compare with its own history? Poly Medicure Ltd's P/E is 47.4×, in the middle of its own history: higher than 49% of past readings. Its usual P/E (the middle reading) is 47.8×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹31.09. Why the multiple is where it is: over the past year earnings per share moved −4.9% while the price moved −25.2%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +10.4% a year; about +15.6% a year came from earnings growth and about −5.2 percentage points from the multiple (the market paying less); over 10 years the price moved +22.8% a year; about +19.2% a year came from earnings growth and about +3.6 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Poly Medicure business getting better or worse? Poly Medicure Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −12.3% in the latest quarter, against +66.0% at its best in 12 quarters, with ROCE falling at 14.4%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Poly Medicure earn on its capital? Poly Medicure Ltd earned a ROCE of 12% in FY26. Its return on capital used (ROIC) is 2.8 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 17.1% net margin and 0.49× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 17.1% net margin × 0.49× asset turnover × 1.24× leverage (assets divided by equity) ≈ 10.4% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 9.2% − 12.0% = −2.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 9.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 11.2%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Poly Medicure have too much debt? Poly Medicure Ltd has total debt of ₹354 Cr against shareholder equity of ₹3,149 Cr as of Jun 2026, so its debt is 0.11× its equity, which is very little. Year by year, that ratio went from 0.12 in FY22 to 0.11 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Poly Medicure shareholding pattern? Foreign institutions cut their stake in Poly Medicure Ltd by 6.5 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 5.4% of the company. Domestic institutions moved +3.6 points over the same period, to 15.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −6.5 points over 8 quarters, to 5.4%; Domestic institutions: +3.6 points over 8 quarters, to 15.9%; Promoters: −0.2 points over 8 quarters, to 62.4%. Why the owners changed: foreign institutions moved −6.5 points and domestic institutions +3.6 points over 8 quarters, while promoters stayed about the same. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Poly Medicure from balance-sheet trouble? For Poly Medicure Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Poly Medicure rank in its industry? 31.9 out of 100, rank 3 of 6 in Medical Equipment, with 100% of the evidence available. Poly Medicure Ltd scores 31.9 out of 100 against the 6 companies it is compared with in Medical Equipment, ranking 3. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 12.5 + 13.3 + 5.2 + 0.9 = 31.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Poly Medicure compared with? Poly Medicure ranks 3 of 6 Medical Equipment companies on the 4-Factor Sector Score, with 31.9 out of 100. 1. [Laxmi Dental Ltd](https://www.sectoralpha.in/stocks/laxmi-dental-ltd) LAXMIDENTL · quiet · Evidence leans up · 68% evidence 53.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 16.7% · Profit 34.8% · Operating margin change 1 points · 100% evidence Capital efficiency 14.5/25 · ROCE 15% · Operating margin 19% · 100% evidence Valuation 10.9/20 · P/E 28.1× · PEG n/a · 15% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -13.9% · 1 year -43.5% · 25% evidence · 0 of 12 weeks ahead Exact sum: 20.4 + 14.5 + 10.9 + 7.5 = 53.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Vasa Denticity Ltd](https://www.sectoralpha.in/stocks/vasa-denticity-ltd) DENTALKART · breaking out · Evidence leans down · 75% evidence 35.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.3/35 · Revenue 17.9% · Profit -30.2% · Operating margin change 1.1 points · 100% evidence Capital efficiency 4.6/25 · ROCE 7% · Operating margin 6.1% · 100% evidence Valuation 6.9/20 · P/E 65× · PEG n/a · 50% evidence Relative strength 9.9/20 · Lead over its industry n/a · Lead over NIFTY 500 -0.8% · 1 year -27.7% · 25% evidence · 8 of 12 weeks ahead Exact sum: 14.3 + 4.6 + 6.9 + 9.9 = 35.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. Poly Medicure Ltd this page POLYMED · quiet · Most evidence points down · 100% evidence 31.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.5/35 · Revenue 18.4% · Profit -12.3% · Operating margin change -2 points · 100% evidence Capital efficiency 13.3/25 · ROCE 12.5% · Operating margin 24% · 100% evidence Valuation 5.2/20 · P/E 45.9× · PEG 3.87 · 100% evidence Relative strength 0.9/20 · Lead over its industry -19.9% · Lead over NIFTY 500 -4.6% · 1 year -27.5% · 100% evidence · 6 of 12 weeks ahead Exact sum: 12.5 + 13.3 + 5.2 + 0.9 = 31.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Tarsons Products Ltd](https://www.sectoralpha.in/stocks/tarsons-products-ltd) TARSONS · losing its lead · Most evidence points down · 75% evidence 29.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 5.8/35 · Revenue 10.6% · Profit -59.7% · Operating margin change -3.5 points · 100% evidence Capital efficiency 6.6/25 · ROCE 4.6% · Operating margin 23.6% · 100% evidence Valuation 5.4/20 · P/E 131× · PEG n/a · 50% evidence Relative strength 11.7/20 · Lead over its industry n/a · Lead over NIFTY 500 22.2% · 1 year 0.7% · 25% evidence · 10 of 12 weeks ahead Exact sum: 5.8 + 6.6 + 5.4 + 11.7 = 29.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Prevest Denpro Ltd](https://www.sectoralpha.in/stocks/prevest-denpro-ltd) PREVEST · Too little evidence to rank firmly · 43% evidence 64.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.5/43.75 · Revenue 17.3% · Profit 17% · Operating margin change -0.6 points · 53% evidence Capital efficiency 23.6/31.25 · ROCE 25.2% · Operating margin 33.9% · 57% evidence Valuation 17.3/25 · P/E 24.8× · PEG n/a · 50% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 23.5 + 23.6 + 17.3 = 64.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 6. [Hemant Surgical Industries Ltd](https://www.sectoralpha.in/stocks/hemant-surgical-industries-ltd) breaking out · Too little evidence to rank firmly · 48% evidence 60.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.0/35 · Revenue 57.2% · Profit 52.9% · Operating margin change -1 points · 48% evidence Capital efficiency 15.6/25 · ROCE 18.9% · Operating margin 9% · 95% evidence Valuation 9.7/20 · P/E 49.2× · PEG n/a · 15% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 67.5% · 1 year n/a · 25% evidence · 8 of 12 weeks ahead Exact sum: 23 + 15.6 + 9.7 + 12.5 = 60.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Equipment](https://www.sectoralpha.in/sectors/medical-equipment), all 6 compared on one page. ## Which companies are close to Poly Medicure in size? Poly Medicure is the largest of 6 Medical Equipment companies on Sector Alpha by market value (scores of 30 October 2026). It is the largest. Just below it: Tarsons Products, Laxmi Dental, Hemant Surgical Industries, Vasa Denticity and Prevest Denpro. ### Medical Equipment companies close in size

1. Poly Medicure Ltd ₹14,692 crore
2. [Tarsons Products Ltd](https://www.sectoralpha.in/stocks/tarsons-products-ltd) ₹1,548 crore
3. [Laxmi Dental Ltd](https://www.sectoralpha.in/stocks/laxmi-dental-ltd) ₹977 crore
4. [Hemant Surgical Industries Ltd](https://www.sectoralpha.in/stocks/hemant-surgical-industries-ltd) ₹834 crore
5. [Vasa Denticity Ltd](https://www.sectoralpha.in/stocks/vasa-denticity-ltd) ₹754 crore
6. [Prevest Denpro Ltd](https://www.sectoralpha.in/stocks/prevest-denpro-ltd) ₹510 crore

[All 6 Medical Equipment companies, largest first](https://www.sectoralpha.in/sectors/medical-equipment#all-companies)

### Companies close in size in other industries

1. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) ₹14,716 crore · Pharma - API & CRAMS
2. [KFin Technologies Ltd](https://www.sectoralpha.in/stocks/kfin-technologies-ltd) ₹14,710 crore · Finance - Capital Markets - RTA
3. Poly Medicure Ltd ₹14,692 crore
4. [Molbio Diagnostics Ltd](https://www.sectoralpha.in/stocks/molbio-diagnostics-ltd) ₹14,682 crore
5. [PVR Inox Ltd](https://www.sectoralpha.in/stocks/pvr-inox-ltd) ₹14,682 crore · Entertainment & Media

## What else do people ask about Poly Medicure? ### What is Poly Medicure's share price today? Poly Medicure Ltd's share price is ₹1,496.20, −25.2% over the past year. The whole company is worth ₹15,160 Cr on the market. In the last 52 weeks it traded between ₹1,230 to ₹1,943; today it is 37% of the way up from the low, 9.5% below its 200-day average (as of 3 November 2026). ### What were Poly Medicure's latest quarterly results? Poly Medicure Ltd reported revenue of ₹525 Cr and net profit of ₹85.0 Cr for the Jun 2026 quarter. Revenue rose 30.3% and profit fell 8.6% compared with a year earlier. Earnings per share were ₹8.49. The operating margin was 24.0%, 2.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Poly Medicure's market cap? Poly Medicure Ltd's market capitalisation is ₹15,160 Cr at a share price of ₹1,496.20. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Poly Medicure performing? Poly Medicure Ltd's share price has been falling for 1 weeks. In its latest quarter, revenue rose 30.3% and profit fell 8.6% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 4 weeks running (as of 3 November 2026). ### Will Poly Medicure's share price go up? This page does not forecast Poly Medicure Ltd's share price. What it shows instead: the share price is ₹1,496.20, and it has been falling for 1 weeks. Its P/E of 47.4× is higher than 49% of its own last 11 years (as of 3 November 2026). ### Who owns Poly Medicure? Promoters own 62.4% of Poly Medicure Ltd, foreign institutions 5.4%, domestic institutions 15.9% and the public 16.3% (latest quarter). The biggest change over the last two years: Foreign institutions cut their stake by 6.5 percentage points over 8 quarters (as of 3 November 2026). ### Does Poly Medicure have too much debt? No, Poly Medicure Ltd has little debt: its debt is 0.11× its equity, and its operating profit is 21 times its interest bill. FY26 borrowings were ₹354 Cr against equity of ₹3,106 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Poly Medicure in its business cycle? Poly Medicure Ltd's FY26 operating margin was 24.0%, against a 13-year range of 21.0% to 28.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 24.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Poly Medicure story? The main question: domestic institutions moved +3.6 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Poly Medicure a stock worth studying right now? What the numbers show: Poly Medicure Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Poly Medicure share price forecast for 2026? What management itself guided: FY27 consolidated revenue ₹2,300-2,400 crore, including full-year Pendra Care and Citieffe consolidation. ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india

This is research, not advice. We’re not SEBI-registered.